Investigator Studies Program (MISP): SARS CoV-2/COVID-19 TREATMENT

Effective January 2021, the Investigator Studies Program Review Committee (MISP-RC) for SARS CoV-2/COVID-19 TREATMENT will accept proposals within our current areas of interest (AOI) up to April 23, 2021. This is a competitive review process that will be conducted in May 2021 by the MISP Review Committee. Decisions will be made on the basis of scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.

The following areas are of interest to Investigator Studies Program Committee:

• In vitro studies to assess the activity of molnupiravir against human Metapneumovirus (hMPV), non-type 2 Dengue virus, rabies, or hantavirus
• Viral evolution, genotype and diversity

Please complete a Preclinical Protocol and detailed budget via Visiontracker, the Company's on-line study management system (in US) or your MSD country representative (outside US). The proposals will be collectively reviewed and selected by the SARS CoV-2/COVID-19 TREATMENT MISP Committee.

Critical Activities and Timelines:

Activity	1st Review Cycle
Proposal Submission with CV and Detailed Budget	April 23, 2021
Target Review Committee Meeting Date	May, 2021
Target Final Comments to Investigator	June, 2021

Queries relating to previously published SARS-CoV02/COVID-19 VACCINES Areas of Interest can be directed to the individual noted under MISP Contacts

Vaccine Confidence MISP proposals relating to SARS-CoV-2 pandemic can be submitted through VACCINES → VACCINE CONFIDENCE